Survival analysis of 1145 lung cancer patients32,33, indicated worse overall outcome for those whose tumors expressed high vs. low levels of GATAD2B (HR = 1.49, P < 2.6E-6, log rank test; Supplementary Fig. 3b), a finding that was even more significant among patients with adenocarcinoma (HR = 1.78, P < 4.1e-06, log rank test; Fig. 2e). The gene discussed is GATAD2B; the disease is lung cancer.